SCHEMBL12377580

SCHEMBL12377580

COc1cccc(P(c2ccccc2)c2ccccc2)c1-c1c(OC)cccc1P(=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.41
HTT P42858 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
NPSR1 Q6W5P4 2/20 0.36
MAPT P10636 3/20 0.34
DRD1 P21728 2/20 0.31
TOP1 P11387 1/20 0.31
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA7 P43166 2/20 0.31
CA9 Q16790 2/20 0.31
CA14 Q9ULX7 2/20 0.31
HTR6 P50406 1/20 0.31
NR3C1 P04150 1/20 0.31
CA4 P22748 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715738 0.86 KMT2A (0.51) KMT2AMEN1HTTALDH1A1POLB
SCHEMBL29430119 0.83 CA1 (0.44) KMT2AMEN1HTTALDH1A1L3MBTL1
SCHEMBL6565552 0.83 CA1 (0.44) KMT2AMEN1HTTALDH1A1L3MBTL1
SCHEMBL301296 0.83 CA1 (0.44) KMT2AMEN1HTTALDH1A1L3MBTL1
SCHEMBL29407955 0.83 CA1 (0.44) KMT2AMEN1HTTALDH1A1L3MBTL1
SCHEMBL1768301 0.81 CA1 (0.43) KMT2AMEN1HTTALDH1A1L3MBTL1
SCHEMBL5572402 0.78 KMT2A (0.44) KMT2AMEN1HTTALDH1A1POLB
SCHEMBL9177262 0.77 KMT2A (0.43) KMT2AMEN1HTTALDH1A1POLB
SCHEMBL5572022 0.77 KMT2A (0.50) KMT2AMEN1HTTALDH1A1POLB
SCHEMBL31550431 0.76 CYP3A4 (0.41) KMT2AMEN1HTTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158424-A1 METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE TAKASAGO INTERNATIONAL CORPORATION (JP) 2024-05-16 US disclosed
EP-4361162-A2 METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE Takasago International Corporation (JP) 2024-05-01 EP disclosed
US-20110190523-A1 HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES FIRMENICH SA (CH) 2011-08-04 US disclosed
WO-2010038209-A1 HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES FIRMENICH SA (CH) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158424-A1 METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE TDO2, SCO2, DUOX1 KMT2A 3643/4885MEN1 2993/4885HTT 4518/4885
US-20110190523-A1 HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES PNN, ADH5, NCL KMT2A 3012/4885MEN1 2081/4885HTT 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.